Artelo biosciences stock.

Artelo Biosciences Inc is a United States based development-stage biopharmaceutical company. It is focused on discovering, licensing, developing and ...Overview News Artelo Biosciences Inc. No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-3.32 Market Cap $4.58 M Shares …Most recently, on Thursday, August 11th, Gregory D. Gorgas bought 1,200 shares of Artelo Biosciences stock. The stock was acquired at an average cost of $4.03 per share, with a total value of $4,836.00. Following the completion of the transaction, the chief executive officer now directly owns 1,200 shares of the company's stock, valued at …--Artelo Biosciences, Inc., a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological ...

Steven D. Reich, MD - Chief Medical Officer. Steven D. Reich, MD has served as our Chief Medical Officer since April 2018. Dr. Reich brought to Artelo over four decades of drug research experience, both as an academically based investigator for Phase I-III trials and as a senior leader in the biopharma industry where he designed and managed ...

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal.

When is Artelo Biosciences's earnings date? Artelo Biosciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, March 29th, 2024 based off last year's report dates. Learn more on ARTL's earnings history.Artelo Biosciences (ARTL) Quote Overview ... It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.Artelo Biosciences Description. Artelo Biosciences Inc is a United States based development-stage biopharmaceutical company. It is focused on discovering, licensing, developing and commercializing treatments that control the endocannabinoid system. The company seeks to pursue technologies and programs that offer proprietary approaches to ...Artelo Biosciences Selected for Oral Presentation at the 32nd Annual ICRS Symposium in Galway, Ireland finance.yahoo.com - June 24 at 8:51 AM: Artelo Biosciences (NASDAQ:ARTLW), Short Interest Report benzinga.com - June 13 at 10:55 PM: Artelo Biosciences to Present at the LD Micro Invitational XII on June 7th …

ART26.12 Program to Target Chemotherapy-Induced Peripheral Neuropathy. $21.3 Million in Cash and Investments as of June 30, 2022. 15-for-1 Reverse Stock Split to be Effective August 10, 2022 ...

Find the latest Evelo Biosciences, Inc. (EVLO) stock quote, history, news and other vital information to help you with your stock trading and investing.

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. Announces Plans to File IND Application in Neuropathic PainSOLANA BEACH, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company ...Artelo Biosciences, Inc. Receives Ethics Approval to Commence Its Cancer Appetite Recovery Phase I/II Clinical Study (CAReS) of ART27.13 for the Treatment of Cancer-Related Anorexia Sep 30 New 90-day low: US$0.7121 июн. 2019 г. ... LA JOLLA, Calif., June 21, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NasdaqCM: ARTL, ARTLW) (the “Company” or “Artelo Biosciences”) ...Artelo Biosciences is a clinical stage company focused on modifying lipid-signaling pathways to improve treatments for people living with cancer (Nasdaq: ...Nov 18, 2023 · Artelo Biosciences Price Performance. ARTL opened at $1.18 on Tuesday. The stock has a market capitalization of $3.37 million, a PE ratio of -0.35 and a beta of 1.40. The firm’s fifty day moving average price is $1.42 and its 200 day moving average price is $1.73. Artelo Biosciences has a 12-month low of $1.16 and a 12-month high of $3.50.

Short Interest. 48.01K ( 09/29/23) Short Interest Change. -42.74%. Percent of Float. 1.68%. Complete Artelo Biosciences Inc. stock information by Barron's. View real-time ARTL stock price and news ... Artelo Biosciences, Inc. (ARTL) มีมูลค่าตลาดของ $4154528 และราคาสดของ $1.44 ตรวจสอบสถิติเพิ่มเติมและเปรียบเทียบกับหุ้นอื่น ๆ และ crypto.Information on stock, financials, earnings, subsidiaries, investors, and executives for Artelo Biosciences. Use the PitchBook Platform to explore the full ...The current price Artelo Biosciences (ARTL) is trading at is $1.23, which is within the analyst’s predicted range. Browse analyst ratings and price targets on all stocks. Popular Channelsartelo biosciences is a biopharmaceutical company dedicated to applying true biopharma discipline in leveraging past research and leading-edge, world-class …

4 дня назад ... Artelo Biosciences, Inc. (Nasdaq: ARTL) announced that George Warren, PhD., will present new preclinical data on ART12.11, a proprietary ...The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. Price Target Upside/Downside. According to ...

--Artelo Biosciences, Inc., a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological ...Artelo Biosciences to Present at Investor Summit Group's Q2 In-Person Conference in New York yahoo.com - April 25 at 8:28 AM: Artelo Biosciences stock soars 40% on pre-clinical data for ART27.13 in cancer-related muscle degeneration seekingalpha.com - April 13 at 9:54 AM Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body.Artelo Biosciences Inc stock performance at a glance. Check Artelo Biosciences Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. artelo biosciences is a biopharmaceutical company dedicated to applying true biopharma discipline in leveraging past research and leading-edge, world-class science to accelerate the development and commercialization of a diverse portfolio of novel, endocannabinoid system modulating therapeutics. our programs have the potential to dramatically improve patient care in major markets. with our ...Artelo Biosciences, Inc. Daily – Vickers Top Insider Picks for 11/21/2023 The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with ... Find the latest analyst research for Artelo Biosciences, Inc. Common Stock (ARTL) at Nasdaq.com.Get the latest Artelo Biosciences, Inc. (ARTL) stock news and headlines to help you in your trading and investing decisions.

Artelo Biosciences Inc. Watch list NEW Set a price target alert After Hours Last Updated: Nov 6, 2023 4:29 p.m. EST Delayed quote $ 1.4092 0.03 2.12% After Hours Volume: 138 Advanced Charting...

Stock analysis for Artelo Biosciences Inc (ARTL:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

The CAReS Trial. Currently, ART27.13 is the focus of a phase 1b/2a, randomized, placebo-controlled trial called the Cancer Appetite Recovery Study (CAReS Trial). The CAReS Trial aims to determine a safe and effective dose as well as activity of ART27.13 in terms of lean body mass, weight gain, and improvement of anorexia.ARTL Stock 12 Months Forecast. $16.67. (1244.35% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Artelo Biosciences in the last 3 months. The average price target is $16.67 with a high forecast of $40.00 and a low forecast of $5.00. The average price target represents a 1244.35% change from the last price of $1.24.Home - Artelo Biosciences. About. Pipeline. Science. Investors. Media. Modifying lipid-signaling pathways to improve treatments for people living with cancer.LA JOLLA, Calif., March 19, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ) , a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced that it has been accepted into the first round …Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023. SOLANA BEACH, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treat...Stock Price Forecast The 3 analysts offering 12-month price forecasts for Artelo Biosciences Inc have a median target of 5.00, with a high estimate of 40.00 and a low estimate of 5.00.About ARTL. Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body.Dec 1, 2023 · Artelo Biosciences Selected for Oral Presentation at the 32nd Annual ICRS Symposium in Galway, Ireland finance.yahoo.com - June 24 at 8:51 AM: Artelo Biosciences (NASDAQ:ARTLW), Short Interest Report benzinga.com - June 13 at 10:55 PM: Artelo Biosciences to Present at the LD Micro Invitational XII on June 7th finance.yahoo.com - June 1 at 9:58 AM Artelo Biosciences, Inc. (ARTLW) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 0.0321 0.0000 (0.00%) At close: 09:47AM EST 1d 5d 1m 6m YTD 1y 5y--Artelo Biosciences, Inc., a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological ...

Artelo Biosciences Inc (ARTL) stock has gained 4.9% while the S&P 500 has fallen -0.12% as of 10:41 AM on Thursday, Nov 30. ARTL has gained $0.07 from the previous closing price of $1.37 on volume of 4,369 shares. Over the past year the S&P 500 is higher by 14.84% while ARTL has fallen -41.46%. ARTL lost -$3.33 per share in the …Artelo Biosciences to Present at Investor Summit Group's Q2 In-Person Conference in New York yahoo.com - April 25 at 8:28 AM: Artelo Biosciences stock soars 40% on pre-clinical data for ART27.13 in cancer-related muscle degeneration seekingalpha.com - April 13 at 9:54 AM Cash on Hand of $15.5M Expected to Support Completion of the CAReS Trial and Operations into Second Half of 2024SOLANA BEACH, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc ...The stock price for . Artelo Biosciences (NASDAQ: ARTLW) is $0.0201 last updated November 14, 2023 at 4:51 PM UTC.Instagram:https://instagram. merger and acquisition companies listcan i trade options in a roth iraovervalued stockgm digital retail platform Artelo Biosciences Inc. 1.37. Delayed Data. As of Nov 29. +0.1427 / +11.60%. Today’s Change. 1.15. Today ||| 52-Week Range. 3.50. webull free stock sign upbest financial advisors in rochester ny Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. ltry stocktwits Dec 1, 2023 · Artelo Biosciences Stock Forecast. ... According to 2 stock analysts, the average 12-month stock price forecast for ARTL stock stock is $32.5, which predicts an ... 41.70%. Get the latest Artelo Biosciences Inc (ARTL) real-time quote, historical performance, charts, and other financial information to help you make more informed …Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body.